EP1173254A2 - Novel treatment of neurotraumatic conditions with a raf inhibitor - Google Patents

Novel treatment of neurotraumatic conditions with a raf inhibitor

Info

Publication number
EP1173254A2
EP1173254A2 EP00927054A EP00927054A EP1173254A2 EP 1173254 A2 EP1173254 A2 EP 1173254A2 EP 00927054 A EP00927054 A EP 00927054A EP 00927054 A EP00927054 A EP 00927054A EP 1173254 A2 EP1173254 A2 EP 1173254A2
Authority
EP
European Patent Office
Prior art keywords
raf
raf inhibitor
inhibitors
neurotraumatic
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00927054A
Other languages
German (de)
French (fr)
Inventor
Elaine Alison Irving
Andrew A. Parsons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9909650.5A external-priority patent/GB9909650D0/en
Priority claimed from GBGB9916655.5A external-priority patent/GB9916655D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1173254A2 publication Critical patent/EP1173254A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Raf protein kinases are key components of signal transduction pathways by which specific extracellular stimuli elicit precise cellular responses in mammalian cells.
  • Activated cell surface receptors activate ras/rap proteins at the inner aspect of the plasmamembrane which in turn recruit and activate Raf proteins.
  • Activated Raf proteins phosphorylate and activate the intracellular protein kinases MEK1 and MEK2.
  • activated MEKs catalyse phosphorylation and activation of p42/p44 mitogen-activated protein kinase (MAPK).
  • a variety of cytoplasmic and nuclear substrates of activated MAPK are known which directly or indirectly contribute to the cellular response to environmental change.
  • Three distinct genes have been identified in mammals that encode Raf proteins; A-Raf, B-Raf and C-Raf (also known as Raf-1) and isoformic variants that result from differential splicing of mRNA are known.
  • Inhibitors of Raf kinases have been suggested for use in disruption of tumor cell growth and hence in the treatment of cancers, e.g. histiocytic lymphoma, lung adenocarcinoma, small cell lung cancer and pancreatic and breast carcinoma.
  • Raf inhibitors are useful in the treatment and/or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events, including cerebral ischemia after cardiac arrest, stroke and multi-infarct dementia and also after cerebral ischemic events such as those resulting from surgery and/or during childbirth.
  • a method of treatment or prophylaxis of a neurotraumatic disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a Raf inhibitor.
  • Raf inhibitor in the manufacture of a medicament for the prophylactic or therapeutic treatment of a disease state in a human, or other mammal, which is exacerbated or caused by a neurotraumatic event.
  • the Raf inhibitor for use in the invention is preferably a B-Raf inhibitor.
  • Neurotraumatic diseases/events as defined herein include both open or penetrating head trauma, such as caused by surgery, or a closed head trauma injury, such as caused by an injury to the head region.
  • ischemic stroke particularly to the brain area, transient ischemic attacks following coronary by-pass and cognitive decline following other transient ischemic conditions.
  • Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel.
  • the definition Raf inhibitor is also intended to encompass antisense constructs that result in a reduced expression of a Raf kinase within a target cell.
  • Small molecule Raf inhibitors include those described in GB2306108,
  • Raf inhibitor 4-(4-chloro-3- hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole.
  • the use of this compound for the treatment of Raf-mediated cancers is described in Poster 3793, American Association of Cancer Research, New Jersey, April 1998.
  • Antisense Raf inhibitors include those described in WO97/10829, US5656612, WO99/02167, US5872232 and WO96/39415.
  • Raf inhibitors In order to use Raf inhibitors in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
  • Inhibitors may conveniently be administered by any of the routes conventionally used for drug administration, for instance, parenterally, orally, topically or by inhalation. Inhibitors may be administered in conventional dosage forms prepared by combining it with standard pharmaceutical carriers according to conventional procedures. Inhibitors may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable carrier is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the pharmaceutical carrier employed may be, for example, either a solid or liquid.
  • solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time delay material well known to the art, such as glyceryl mono- stearate or glyceryl distearate alone or with a wax.
  • time delay material well known to the art, such as glyceryl mono- stearate or glyceryl distearate alone or with a wax.
  • a wide variety of pharmaceutical forms can be employed.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will van'
  • the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule or nonaqueous liquid suspension.
  • Inhibitors are preferably administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration.
  • the intravenous form of parenteral administration is generally preferred.
  • Appropriate dosage forms for such administration may be prepared by conventional techniques.
  • Inhibitors may also be administered orally.
  • Appropriate dosage forms for such administration may be prepared by conventional techniques.
  • Inhibitors may also be administered by inhalation, that is by intranasal and oral inhalation administration.
  • Appropriate dosage forms for such administration such as aerosol formulations, may be prepared by conventional techniques.
  • Inhibitors may also be administered topically, that is by non-systemic administration. This includes the application of the inhibitors externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
  • the daily oral dosage regimen will preferably be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to 30 mg kg, more preferably from about 0.5 mg to 15mg.
  • the daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg.
  • the daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily.
  • the daily inhalation dosage regimen will preferably be from about 0.01 mg kg to about 1 mg kg per day.
  • the optimal quantity and spacing of individual dosages of the inhibitors will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the inhibitors given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
  • the sub-title compound was prepared from 4-chloro-3-methoxybenzoic acid, via its acid chloride, by analogy to the five step procedure (general method B) described by T. F. Gallagher et al, Bioorg. Med. Chem., (1997), 5, 49: MS m/z 362/364 M ⁇ + (electrospray).
  • step b) 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole Boron tribromide (5.6 ml, 1M in dichloromethane, 5.6mmol) was added to an ice-cooled solution of the product of step a) (670 mg, 1.85 mmol) in dichloromethane (20 ml). The solution was allowed to warm to ambient temperature and stirred for a further 16h. 5M hydrochloric acid (5 ml) was then added and the mixture heated to reflux for 30 min. After cooling the solution was made alkaline with 40% aqueous sodium hydroxide and the solid product collected by filtration. The residue was washed with ethyl acetate to afford the title compound as a yellow solid: MS m/z 348/350 M ⁇ + (electrospray).
  • the activity of compounds as Raf inhibitors may be determined by the following in vitro assay: Raf Kinase assay
  • MAP kinase MAP kinase
  • Catalytically active human recombinant B-Raf protein was obtained by purification from sf9 insect cells infected with a human B-Raf recombinant baculovirus expression vector. To ensure that all substrate phosphorylation resulted from B-Raf activity, a catalytically inactive form of MEK was utilised.
  • This protein was purified from bacterial cells expression mutant inactive MEK as a fusion protein with glutathione-S-transferase (GST- kdMEK).
  • GST- kdMEK glutathione-S-transferase
  • the neuroprotective properties of Raf inhibitors may be determined by the following in vitro assay: Neuroprotective properties of 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4- pyridyl)-lH-imidazole in rat hippocampal slice cultures
  • Organotypic cultures provide an intermediate between dissociated neuronal cell cultures and in-vivo models of oxygen and glucose deprivation (OGD).
  • OGD oxygen and glucose deprivation
  • the majority of glial-neuronal interactions and neuronal circuitry are maintained in cultured hippocampal slices, so facilitating investigation of the patterns of death among differing cell types in a model that resembles the in vivo situation.
  • These cultures allow the study of delayed cellular damage and death 24 hours, or more, post-insult and permit assessment of the consequences of long-term alterations in culture conditions.
  • Bound PI shows increased emission at 635nm when excited at 540nm.
  • One PI fluorescence image and one white light image are taken and the proportion of cell death analysed.
  • the area of region CA1 is defined from the white light image and superimposed over the PI image.
  • the PI signal is thresholded and area of PI damage expressed as a percentage of the CA1 area. Correlation between PI fluorescence and histo logically confirmed cell death has been validated previously by Nissl-staining using cresyl fast violet (Newell et al, J Neurosci., (1995b) 15: 7702-7711).
  • B-Raf inhibitors are effective inhibitor of the catalytic activity of human B-Raf protein kinase towards its physiologic substrate MAP kinase (MEK). Moreover, B-Raf inhibitors are potent inhibitors of neuronal cell death that results from oxygen glucose deprivation in hippocampal slice cultures. Such neuroprotective properties indicate that B-Raf inhibitors are likely to be of value in prevention of neuronal cell death associated with ischemic stroke and trauma injury.
  • MEK MAP kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of Raf kinase inhibitors in the treatment of neurotraumatic diseases.

Description

NOVEL TREATMENT
This invention relates to the use of Raf kinase inhibitors in the treatment of neurotraumatic diseases. Raf protein kinases are key components of signal transduction pathways by which specific extracellular stimuli elicit precise cellular responses in mammalian cells. Activated cell surface receptors activate ras/rap proteins at the inner aspect of the plasmamembrane which in turn recruit and activate Raf proteins. Activated Raf proteins phosphorylate and activate the intracellular protein kinases MEK1 and MEK2. In turn, activated MEKs catalyse phosphorylation and activation of p42/p44 mitogen-activated protein kinase (MAPK). A variety of cytoplasmic and nuclear substrates of activated MAPK are known which directly or indirectly contribute to the cellular response to environmental change. Three distinct genes have been identified in mammals that encode Raf proteins; A-Raf, B-Raf and C-Raf (also known as Raf-1) and isoformic variants that result from differential splicing of mRNA are known.
Inhibitors of Raf kinases have been suggested for use in disruption of tumor cell growth and hence in the treatment of cancers, e.g. histiocytic lymphoma, lung adenocarcinoma, small cell lung cancer and pancreatic and breast carcinoma.
It has now been discovered that Raf inhibitors are useful in the treatment and/or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events, including cerebral ischemia after cardiac arrest, stroke and multi-infarct dementia and also after cerebral ischemic events such as those resulting from surgery and/or during childbirth.
Thus according to the invention there is provided a method of treatment or prophylaxis of a neurotraumatic disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a Raf inhibitor.
According to the invention there is also provided the use of a Raf inhibitor in the manufacture of a medicament for the prophylactic or therapeutic treatment of a disease state in a human, or other mammal, which is exacerbated or caused by a neurotraumatic event.
The Raf inhibitor for use in the invention is preferably a B-Raf inhibitor. Neurotraumatic diseases/events as defined herein include both open or penetrating head trauma, such as caused by surgery, or a closed head trauma injury, such as caused by an injury to the head region. Also included within this definition is ischemic stroke, particularly to the brain area, transient ischemic attacks following coronary by-pass and cognitive decline following other transient ischemic conditions. Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel. Roles for stress stimuli (such as anoxia), redox injury, excessive neuronal excitatory stimulation and inflammatory cytokines in this area has been emerging and the present invention provides a means for the potential treatment of these injuries. Relatively little treatment, for an acute injury such as these has been available.
Models of closed head injuries and treatment with mixed 5-LO/CO agents is discussed in Shohami et al, J. Vaisc. & Clinical Physiology and Pharmacology, (1992), 3(2), 99-107.
Suitable Raf inhibitors for use in the method of the invention include small molecule and peptides. The definition Raf inhibitor is also intended to encompass antisense constructs that result in a reduced expression of a Raf kinase within a target cell. Small molecule Raf inhibitors include those described in GB2306108,
WO98/22103, WO98/52559, WO98/50370, WO99/10325 and W099/17759.
N particular Raf inhibitor that may be mentioned is 4-(4-chloro-3- hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole. The use of this compound for the treatment of Raf-mediated cancers is described in Poster 3793, American Association of Cancer Research, New Orleans, April 1998.
Antisense Raf inhibitors include those described in WO97/10829, US5656612, WO99/02167, US5872232 and WO96/39415.
In order to use Raf inhibitors in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
Inhibitors may conveniently be administered by any of the routes conventionally used for drug administration, for instance, parenterally, orally, topically or by inhalation. Inhibitors may be administered in conventional dosage forms prepared by combining it with standard pharmaceutical carriers according to conventional procedures. Inhibitors may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable carrier is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono- stearate or glyceryl distearate alone or with a wax. A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will van'
- 1 - widely but preferably will be from about 25mg to about lg. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule or nonaqueous liquid suspension.
Inhibitors are preferably administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The intravenous form of parenteral administration is generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques.
Inhibitors may also be administered orally. Appropriate dosage forms for such administration may be prepared by conventional techniques.
Inhibitors may also be administered by inhalation, that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as aerosol formulations, may be prepared by conventional techniques.
Inhibitors may also be administered topically, that is by non-systemic administration. This includes the application of the inhibitors externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
For all methods of use disclosed herein for inhibitors, the daily oral dosage regimen will preferably be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to 30 mg kg, more preferably from about 0.5 mg to 15mg. The daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg. The daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily. The daily inhalation dosage regimen will preferably be from about 0.01 mg kg to about 1 mg kg per day. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of the inhibitors will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the inhibitors given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.
EXAMPLE 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole a) 4-(4-Chloro-3-methoxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole
The sub-title compound was prepared from 4-chloro-3-methoxybenzoic acid, via its acid chloride, by analogy to the five step procedure (general method B) described by T. F. Gallagher et al, Bioorg. Med. Chem., (1997), 5, 49: MS m/z 362/364 MΗ+ (electrospray). b) 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole Boron tribromide (5.6 ml, 1M in dichloromethane, 5.6mmol) was added to an ice-cooled solution of the product of step a) (670 mg, 1.85 mmol) in dichloromethane (20 ml). The solution was allowed to warm to ambient temperature and stirred for a further 16h. 5M hydrochloric acid (5 ml) was then added and the mixture heated to reflux for 30 min. After cooling the solution was made alkaline with 40% aqueous sodium hydroxide and the solid product collected by filtration. The residue was washed with ethyl acetate to afford the title compound as a yellow solid: MS m/z 348/350 MΗ+ (electrospray).
BIOLOGICAL EXAMPLES
The activity of compounds as Raf inhibitors may be determined by the following in vitro assay: Raf Kinase assay
Activity of human recombinant B-Raf protein was assessed in vitro by assay of the incorporation of radiolabelled phosphate to recombinant MAP kinase (MEK), a known physiologic substrate of B-Raf. Catalytically active human recombinant B-Raf protein was obtained by purification from sf9 insect cells infected with a human B-Raf recombinant baculovirus expression vector. To ensure that all substrate phosphorylation resulted from B-Raf activity, a catalytically inactive form of MEK was utilised. This protein was purified from bacterial cells expression mutant inactive MEK as a fusion protein with glutathione-S-transferase (GST- kdMEK). Method: Standard assay conditions of B-Raf catalytic activity utilised 3ug of
GST-kdMEK, lOuM ATP and 2uCi 33P-ATP, 50mM MOPS, 0.1 mM EDTN 0.1M sucrose, lOmM MgCl2 plus 0.1% dimethylsulphoxide (containing compound where appropriate) in a total reaction volume of 30ul. Reactions were incubated at 25°C for 90 minutes and reactions terminated by addition of EDTA to a final concentration of 50uM. lOul of reaction was spotted to P30 phosphocellulose paper and air dried. Following four washes in ice cold 10% trichloroacetic acid, 0.5% phosphoric acid, papers were air dried prior to addition of liquid scintillant and measurement of radioactvity in a scintillation counter. Results: 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole was found to be effective in inhibiting B-Raf mediated phosphorylation of GST- kdMEK substrate (IC50 24nm). The activity of compounds as Raf inhibitors may also be determined by the assays described in WO 99/10325, McDonald, O.B., Chen, W.J., Ellis, B., Hoffman, C, Overton, L., Rink, M., Smith, A., Marshall, C.J. and Wood, E.R. (1999) "A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high throughput screening and identification of selective enzyme inhibitors.", Anal. Biochem., 268: 318-329 and ANCR meeting New Orleans 1998 Poster 3793.
The neuroprotective properties of Raf inhibitors may be determined by the following in vitro assay: Neuroprotective properties of 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4- pyridyl)-lH-imidazole in rat hippocampal slice cultures
Organotypic cultures provide an intermediate between dissociated neuronal cell cultures and in-vivo models of oxygen and glucose deprivation (OGD). The majority of glial-neuronal interactions and neuronal circuitry are maintained in cultured hippocampal slices, so facilitating investigation of the patterns of death among differing cell types in a model that resembles the in vivo situation. These cultures allow the study of delayed cellular damage and death 24 hours, or more, post-insult and permit assessment of the consequences of long-term alterations in culture conditions. A number of laboratories have reported delayed neuronal damage in response to OGD in organotypic cultures of the hippocampus (Vornov et al, Stroke, (1994) 25: 457-465, Newell et al, Brain Res., (1995a) 676: 38-44). Several classes of compounds have been shown to protect in this model, including EAA antagonists (Strasser et al, Brain Res., (1995) 687: 167-174), Na channel blockers (Tasker et al, JNeurosci., (1992) 12: 4298-4308) and Ca channel blockers (Pringle et al, Stroke, (1996) 27: 2124-2130). To date, relatively little is known of the roles of intracellular kinase mediated signalling pathways in neuronal cell death in this model.
Method: Organotypic hippocampal slice cultures were prepared using the method of Stoppini et al, J. Neurosci. Methods., (1991) 37, 173-182. Briefly, 400 micron sections prepared from hippocampi of 7-8 day postnatal Sprague Dawley rats are cultured on semiporous membranes for 9-12 days. OGD is then induced by incubation in serum and glucose-free medium in an anaerobic chamber for 45 minutes. Cultures are then returned to the air / CO2 incubator for 23 hours before analysis. Propidium iodide (PI) is used as an indicator of cell death. PI is non toxic to neurones and has been used in many studies to ascertain cell viability. In damaged neurons PI enters and binds to nucleic acids. Bound PI shows increased emission at 635nm when excited at 540nm. One PI fluorescence image and one white light image are taken and the proportion of cell death analysed. The area of region CA1 is defined from the white light image and superimposed over the PI image. The PI signal is thresholded and area of PI damage expressed as a percentage of the CA1 area. Correlation between PI fluorescence and histo logically confirmed cell death has been validated previously by Nissl-staining using cresyl fast violet (Newell et al, J Neurosci., (1995b) 15: 7702-7711). Results: 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4-pyridyl)- 1 H-imidazole showed significant protection when pre-incubated 1 hour before a 45 minute OGD (Figure 1). The IC50 for this protection was approximately lOOnM.
Figure 1 : Effect of 4-(4-chloro-3-hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole on oxygen-glucose deprivation-induced neuronal cell death in organotypic hippocampal culture. Duration of OGD 45 minutes. The graph shows the percentage of the neuronal CA1 area that is dead as defined by PI staining. Control values are between 65-75 percent. Results are shown as mean ± SEM *** (P=<0.0005) n= 6-12.
Conclusions: B-Raf inhibitors are effective inhibitor of the catalytic activity of human B-Raf protein kinase towards its physiologic substrate MAP kinase (MEK). Moreover, B-Raf inhibitors are potent inhibitors of neuronal cell death that results from oxygen glucose deprivation in hippocampal slice cultures. Such neuroprotective properties indicate that B-Raf inhibitors are likely to be of value in prevention of neuronal cell death associated with ischemic stroke and trauma injury.

Claims

Claims:
1. A method of treatment or prophylaxis of a neurotraumatic disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a
Raf inhibitor.
2. The use of a Raf inhibitor in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by a neurotraumatic event.
3. The method or use according to claim 1 or 2 wherein the Raf inhibitor is a small molecule Raf inhibitor.
4. The method or use according to any one of the preceding claims wherein the Raf inhibitor is a B-Raf inhibitor.
5. The method or use according to claim 4 wherein the B-Raf inhibitor is 4-(4- chloro-3-hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole.
6. The method or use according to any one of the preceding claims wherein the neurotraumatic disease is ischemic stroke.
7. The method or use according to any one of the preceding claims wherein the neurotraumatic disease is caused by surgery, or is an open head injury.
8. The method or use according to any one of the preceding claims wherein the neurotraumatic disease is a closed head injury.
EP00927054A 1999-04-27 2000-04-26 Novel treatment of neurotraumatic conditions with a raf inhibitor Withdrawn EP1173254A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9909650 1999-04-27
GBGB9909650.5A GB9909650D0 (en) 1999-04-27 1999-04-27 Novel treatment
GB9916655 1999-07-15
GBGB9916655.5A GB9916655D0 (en) 1999-07-15 1999-07-15 Novel treatment
PCT/EP2000/003730 WO2000064422A2 (en) 1999-04-27 2000-04-26 Novel treatment of neurotraumatic conditions with raf inhibitor

Publications (1)

Publication Number Publication Date
EP1173254A2 true EP1173254A2 (en) 2002-01-23

Family

ID=26315478

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00927054A Withdrawn EP1173254A2 (en) 1999-04-27 2000-04-26 Novel treatment of neurotraumatic conditions with a raf inhibitor

Country Status (4)

Country Link
EP (1) EP1173254A2 (en)
JP (1) JP2002542280A (en)
AU (1) AU4556800A (en)
WO (1) WO2000064422A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1529901A (en) 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
WO2004019873A2 (en) 2002-08-29 2004-03-11 Scios Inc. Methods of promoting osteogenesis
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
MXPA06014696A (en) * 2004-06-15 2007-02-12 Astrazeneca Ab Substituted quinazolones as anti-cancer agents.
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson &amp; Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017156A1 (en) * 1990-05-10 1991-11-14 Pfizer Inc Neuroprotective indolone and related derivatives
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
WO1994015645A1 (en) * 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against genes of the raf oncogene family
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
EP0889887A4 (en) * 1996-03-25 2003-06-11 Smithkline Beecham Corp Novel treatment for cns injuries
CA2272578A1 (en) * 1996-11-18 1998-05-28 Mcgill University Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO0064422A3 *

Also Published As

Publication number Publication date
JP2002542280A (en) 2002-12-10
WO2000064422A2 (en) 2000-11-02
AU4556800A (en) 2000-11-10
WO2000064422A3 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
Jane et al. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells
EP1318992B1 (en) Imidazole derivatives as raf kinase inhibitors
JP7671327B2 (en) Combination therapy for the treatment of gastrointestinal stromal tumors
EP1263753B1 (en) Imidazol derivatives as raf kinase inhibitors
EP1397354B1 (en) Imidazole-2-carboxamide derivatives as raf kinase inhibitors
US20120238597A1 (en) Inhibiting EPH B-3 Kinase
EP1755611A1 (en) Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
JP2023521753A (en) antiviral therapy
EP1423383B1 (en) Pyridine substituted furan derivatives as raf kinase inhibitors
CA2534432A1 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
CZ93097A3 (en) 5-ht1f mediated inhibition of neurogenic meningeal extravasate
CN111053768A (en) Pharmaceutical combination for the treatment of melanoma
JPH04226917A (en) Prophylactic and therapeutic drug for nerve atrophy in advance
EP1173254A2 (en) Novel treatment of neurotraumatic conditions with a raf inhibitor
EP1313478A2 (en) Method for treatment of migraine using pde5 inhibitors
EP1432697A1 (en) Pyridylfurans and pyrroles as raf kinase inhibitors
Li et al. Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells
US20080045500A1 (en) Nerve Regeneration Stimulator
US20040192689A1 (en) Heterocycle-carboxamide derivatives as raf kinase inhibitors
EP1432702B1 (en) Nitrogen-containing heterocyclic compounds and their use as raf inhibitors
EP4433054A1 (en) Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
US20040198730A1 (en) Pyridylfurans and pyrroles as raf kinase inhibitors
US20240366601A1 (en) Methods for treating traumatic brain injury
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma
Elkhrbash The role of angiotensin AT1 and AT2 receptors in the development of apoptosis and inflammation following experimental myocardial infarction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011015

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

17Q First examination report despatched

Effective date: 20031127

RTI1 Title (correction)

Free format text: TREATMENT OF NEUROTRAUMATIC CONDITIONS WITH A RAF INHIBITOR

17Q First examination report despatched

Effective date: 20031127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070524